Form 8-K - Current report:
SEC Accession No. 0001193125-25-140329
Filing Date
2025-06-13
Accepted
2025-06-13 07:33:24
Documents
13
Period of Report
2025-06-12
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d945713d8k.htm   iXBRL 8-K 29806
2 EX-3.1 d945713dex31.htm EX-3.1 9997
  Complete submission text file 0001193125-25-140329.txt   165640

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA snse-20250612.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE snse-20250612_lab.xml EX-101.LAB 19482
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE snse-20250612_pre.xml EX-101.PRE 12149
15 EXTRACTED XBRL INSTANCE DOCUMENT d945713d8k_htm.xml XML 3952
Mailing Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850
Business Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 (240) 243-8000
Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39980 | Film No.: 251044741
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)